Clinical trial

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

NCT01772199

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention GSK239512 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-02-01

PhasePHASE2

Conditions

Multiple Sclerosis, Relapsing-Remittingunresolved

Interventions

GSK239512DRUG

PlaceboDRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

MadridSpain3 SofiaBulgaria3 BarcelonaSpain2 LondonUnited Kingdom2 MontrealQuebec, Canada1 SevilleSpain1 OttawaOntario, Canada1 EdmontonAlberta, Canada1 CalgaryAlberta, Canada1 StockholmSweden1 MálagaSpain1 KyivUkraine1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01772199 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.